Ampa Health is a neurotechnology company focused on building scalable neuromodulation technology for treating mental health disorders such as major depressive disorder and treatment-resistant depression.

The company’s core product, Ampa One, is an FDA-cleared transcranial magnetic stimulation (TMS) system designed to be lightweight, camera-guided, and easier for clinicians to deploy than traditional TMS devices. The system integrates neuronavigation and simplified operational workflows to support precision targeting of brain circuits associated with emotional regulation.

Ampa’s technology is positioned for clinical use by mental health providers and treatment centers, aiming to broaden access to evidence-based brain stimulation. The platform supports expanded deployment models including satellite clinics and tele-supervision, and the company is advancing protocols to shorten traditional multi-week TMS courses.